Personalis, Inc. - Common Stock (NQ:PSNL)

15.98 -0.02 (-0.09%)

Delayed Quote Updated: 11:32 AM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

PSNL Merger Notice: BFA Law Notifies Personalis Shareholders of the Ongoing Investigation into the $16.25 per Share Merger

Today 6:07 EDT

BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders...

Via Newsfile

Topics Artificial Intelligence

Investor Notification: Personalis, Inc. ($PSNL) Investors Are Reminded to Contact BFA Law About the Ongoing Investigation into $16.25 per Share Merger Deal

October 24, 2026

Via Newsfile

Topics Artificial Intelligence

PSNL Securities Notice: Personalis, Inc. Shareholders Are Notified to Contact BFA Law About Its Pending Investigation into the $16.25 per Share Merger Deal

October 22, 2026

Via Newsfile

Topics Artificial Intelligence

PSNL Stock Notification: Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced – Investors are Alerted to Contact BFA Law

October 21, 2026

From Bleichmar Fonti & Auld LLP

Via Business Wire

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

October 21, 2026

From Personalis, Inc.

Via Business Wire

Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

October 20, 2026

From Personalis, Inc.

Via Business Wire

Halper Sadeh LLC is Investigating Whether CSR, FULC, WEAV, PSNL are Obtaining Fair Deals for their Shareholders

September 23, 2026

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)

September 23, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

September 09, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

September 03, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether UTZ, PSNL, DSGR are Obtaining Fair Deals for their Shareholders

August 07, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Personalis Reports Second Quarter Results and Recent Highlights

August 04, 2026

From Personalis, Inc.

Via Business Wire

Halper Sadeh LLC is Investigating Whether UTZ, BLFS, FNWD, PSNL are Obtaining Fair Deals for their Shareholders

July 30, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Shareholders

July 29, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether LXP, FNWD, PSNL are Obtaining Fair Deals for their Shareholders

July 28, 2026

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)

July 27, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether UTZ, PSNL, LXP are Obtaining Fair Deals for their Shareholders

July 22, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL

July 21, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

July 21, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders

July 20, 2026

From Halper Sadeh LLC

Via Business Wire

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

July 20, 2026

From Personalis, Inc.

Via Business Wire

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

July 14, 2026

From Personalis, Inc.

Via Business Wire

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

June 09, 2026

From Personalis, Inc.

Via Business Wire

Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors? ↗

June 04, 2026

This cancer genomics specialist, serving major biopharma and research clients, reported a notable insider sale in its latest SEC filing.

Via The Motley Fool

Topics Regulatory Compliance

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

June 02, 2026

From Personalis, Inc.

Via Business Wire

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

May 26, 2026

From Personalis, Inc.

Via Business Wire

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

May 20, 2026

From Personalis, Inc.

Via Business Wire

Personalis to Participate in Upcoming Investor Events

May 14, 2026

From Personalis, Inc.

Via Business Wire

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

May 13, 2026

From Personalis, Inc.

Via Business Wire

Personalis Q1 Earnings Call Highlights ↗

May 08, 2026

Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business...

Via MarketBeat

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.